Core Viewpoint - Addex Therapeutics reported a significant decrease in net results for the third quarter of 2024, with a net loss of CHF 1.5 million compared to a net profit of CHF 12.9 million in the previous quarter, primarily due to a nonrecurring gain from a business sale in the second quarter [2][3] Financial Performance - The provisional net loss for Q3 2024 was CHF 1.5 million, a decrease of CHF 14.4 million from the net profit of CHF 12.9 million in Q2 2024 [2] - For the nine-month period ending September 30, 2024, Addex reported a net profit of CHF 8.3 million, down from CHF 9.8 million for the six-month period ending June 30, 2024 [3] - As of September 30, 2024, Addex's cash position was CHF 3.3 million [3] Upcoming Events - Addex is scheduled to release its third quarter 2024 financial results on November 22, 2024, with a teleconference and webcast for investors and analysts [4]
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024